Svennilson Peter
Follow13F filer, CIK 1606074, SAN FRANCISCO, CA
Svennilson Peter reported $349,925,000 across 4 holdings for the quarter ended 2019-06-30, in a 13F-HR filed 2019-08-14.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001600420-19-000007
- Period
- 2019-06-30
- Reported value
- $350M
- Holdings
- 4
- Top 10 weight
- 100%
- New
- 1
- Sold out
- 1
Stakes and trades reported after 2019-06-30
13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.
- SRZN SURROZEN INC: 13D/A 3,813,501 shares, 18.2% of the class, 13D/A filed 2026-11-18, 0001193125-26-467393Timeline
Accepted , ingested - TNYA TENAYA THERAPEUTICS INC: 13D/A 49,313,559 shares, 21.6% of the class, 13D/A filed 2026-11-16, 0001193125-26-463722Timeline
Accepted , ingested
Largest buys vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| NGM BIOPHARMACEUTICALS INCnew | +15,694,091 | $230M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| IMMUNE DESIGN CORP.exited | -6,642,942 | -$38.9M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q2 2019
Share positions as resolved from 13F-HR 0001600420-19-000007, largest first. % of portfolio is the value over $349,925,000, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| NGM BIOPHARMACEUTICALS INCNGM BIOPHARMACEUTICALS INC | 15,694,091 | $230M | 65.66% | new | |||
| CONSTELLATION PHARMACEUTICALCONSTELLATION PHARMACEUTICAL | 4,677,939 | $57.4M | 16.42% | 0 | |||
| GRITSTONE BIO INCGRITSTONE BIO INC | 3,102,934 | $34.6M | 9.88% | 0 | |||
| RCUSARCUS BIOSCIENCES INC | 3,540,850 | $28.1M | 8.04% | 0 | Timeline |
Sold out in Q2 2019
Positions in the previous quarter's report that this quarter's report no longer lists.
| Security | Shares before | Value before | Type |
|---|---|---|---|
| IMMUNE DESIGN CORP.IMMUNE DESIGN CORP. | 6,642,942 | $38.9M | shares |
How Q2 2019 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0001600420-19-000007 | base | 2019-08-14 | acceptance time not in the bulk data set |